Zymeworks’ (ZYME) Market Outperform Rating Reiterated at Citizens Jmp

Citizens Jmp reaffirmed their market outperform rating on shares of Zymeworks (NASDAQ:ZYME) in a report issued on Wednesday,Benzinga reports. The firm currently has a $32.00 price objective on the stock.

ZYME has been the topic of a number of other reports. Wells Fargo & Company boosted their price target on shares of Zymeworks from $37.00 to $40.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. B. Riley Financial reiterated a “buy” rating and set a $44.00 target price (up from $40.00) on shares of Zymeworks in a research report on Monday, August 10th. Deutsche Bank Aktiengesellschaft set a $32.00 price target on shares of Zymeworks in a research report on Wednesday. Stifel Nicolaus set a $46.00 price target on shares of Zymeworks in a research note on Friday, August 7th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Zymeworks in a report on Wednesday. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Zymeworks presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

Zymeworks Price Performance

ZYME opened at $28.27 on Wednesday. Zymeworks has a 1 year low of $13.60 and a 1 year high of $30.62. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -14.00 and a beta of 1.15. The firm’s fifty day moving average price is $24.95 and its two-hundred day moving average price is $24.84.

Zymeworks (NASDAQ:ZYME) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.06). The firm had revenue of $3.23 million for the quarter, compared to analysts’ expectations of $4.54 million. Zymeworks had a negative return on equity of 72.30% and a negative net margin of 405.31%.The firm’s revenue for the quarter was down 90.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.03 earnings per share. As a group, equities analysts anticipate that Zymeworks will post 1.37 EPS for the current year.

Zymeworks declared that its board has authorized a share buyback plan on Thursday, May 14th that authorizes the company to buyback $125.00 million in shares. This buyback authorization authorizes the company to buy up to 7% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

Institutional Investors Weigh In On Zymeworks

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Zymeworks in the second quarter worth about $111,122,000. Siren L.L.C. purchased a new position in Zymeworks during the fourth quarter valued at approximately $44,238,000. Rubric Capital Management LP increased its holdings in Zymeworks by 21.7% during the 1st quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock worth $175,280,000 after acquiring an additional 1,250,000 shares during the period. Perceptive Advisors LLC increased its holdings in Zymeworks by 56.0% during the 4th quarter. Perceptive Advisors LLC now owns 3,261,850 shares of the company’s stock worth $85,885,000 after acquiring an additional 1,171,187 shares during the period. Finally, Millennium Management LLC lifted its stake in Zymeworks by 851.6% in the 3rd quarter. Millennium Management LLC now owns 1,104,813 shares of the company’s stock worth $18,870,000 after purchasing an additional 988,711 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors.

Key Headlines Impacting Zymeworks

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Ziihera (zanidatamab-hrii), both with and without tislelizumab plus chemotherapy, for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma. The expanded approval broadens Zymeworks’ commercial opportunity and could improve the long-term revenue outlook for its lead product. FDA approves Ziihera for first-line HER2-positive advanced gastroesophageal cancer
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $55 price target while sharply raising its earnings outlook. Its FY2026 EPS estimate increased to $1.51 from $0.31, and its FY2027 estimate moved to $1.32 from a prior loss estimate of $1.72 per share. The firm also raised several quarterly forecasts, signaling greater confidence in Ziihera-related earnings potential. HC Wainwright raises Zymeworks earnings estimates
• Positive Sentiment: Citigroup reportedly forecast substantial price appreciation, while Citizens JMP assigned Zymeworks a market outperform rating. These calls add further analyst support following the FDA decision. Citigroup forecasts strong price appreciation for Zymeworks Citizens JMP rates Zymeworks market outperform
• Neutral Sentiment: The immediate catalyst is primarily regulatory and expectations-driven; investors will likely look for prescription growth, launch execution and evidence that the approval translates into sustainable revenue and earnings.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.